Characteristic | Chemorefractory group | Chemosensitive group |
---|---|---|
Total (cases) | 12 | 16 |
Age [years; median (range)] | 60.5 (47–72) | 57 (36–78) |
  < 40 [cases (%)] | 0 (0) | 2 (12.5) |
 40–49 [cases (%)] | 1 (8.3) | 1 (6. 3) |
 50–59 [cases (%)] | 4 (33.3) | 9 (56.3) |
 60–69 [cases (%)] | 5 (41.7) | 2 (12.5) |
  ≥ 70 [cases (%)] | 2 (16.7) | 2 (12.5) |
Gender [cases (%)] | ||
 Male | 11 (91.7) | 9 (56.3) |
 Female | 1 (8.3) | 7 (43.8) |
Disease stage [cases (%)] | ||
 Limited stage | 3 (25.0) | 12 (75.0) |
 Extensive stage | 9 (75.0) | 4 (25.0) |
Cycles of first-line regimen [cases (%)] | ||
 1–2 | 5 (41.7) | 0 (0.0) |
 3–4 | 3 (25.0) | 5 (31.3) |
 5–6 | 4 (33.3) | 11 (68.8) |
Follow-up [months; median (range)] | 10 (5–16) | 43.5 (26–103) |